Sugi Predict

Sugi Predict / Compounds / SCHEMBL10587

SCHEMBL10587

SCHEMBL10587

Brc1c[nH]c2ccncc12

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 3/20 0.59
▸ HASPIN Q8TF76 3/20 0.59
▸ CCNT1 O60563 1/20 0.59
▸ CDK9 P50750 1/20 0.59
▸ HTR6 P50406 2/20 0.51
▸ AXL P30530 2/20 0.46
▸ GSK3B P49841 3/20 0.43
▸ DYRK1A Q13627 3/20 0.43
▸ NFATC1 O95644 2/20 0.43
▸ ACHE P22303 3/20 0.42
▸ IMPDH2 P12268 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ GPR84 Q9NQS5 1/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ TGFBR1 P36897 1/20 0.38
▸ IKBKE Q14164 1/20 0.38
▸ TDO2 P48775 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30295197 1.00 PIM1 (0.59) PIM1HASPINCCNT1CDK9HTR6
SCHEMBL29814872 0.83 PIM1 (0.59) PIM1HASPINCCNT1CDK9AXL
SCHEMBL1892610 0.83 PIM1 (0.59) PIM1HASPINCCNT1CDK9AXL
SCHEMBL16168495 0.75 HTR6 (0.56) PIM1HASPINCCNT1CDK9HTR6
SCHEMBL2050489 0.75 HASPIN (0.59) PIM1HASPINCCNT1CDK9HTR6
SCHEMBL30067091 0.75 HASPIN (0.59) PIM1HASPINCCNT1CDK9HTR6
SCHEMBL14059758 0.75 GSK3B (0.51) PIM1HASPINCCNT1CDK9HTR6
SCHEMBL3224448 0.75 ATM (0.52) PIM1HASPINCCNT1CDK9HTR6
SCHEMBL29535106 0.75 ATM (0.52) PIM1HASPINCCNT1CDK9HTR6
SCHEMBL15634812 0.75 GSK3B (0.48) PIM1HASPINCCNT1CDK9AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4687883-A2 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-12404275-B2 Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof PRIMEGENE (BEIJING) CO., LTD. (CN) 2025-09-02 — — US disclosed
EP-3954685-B1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF US HEALTH (US) 2025-08-27 — — EP disclosed
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2025-07-22 — — US disclosed
US-20250136606-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2025-05-01 — — US disclosed
US-20240398812-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
US-20240368087-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2024-11-07 — — US disclosed
WO-2024211249-A2 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2024-10-10 — — WO disclosed
EP-4408850-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2024-08-07 — — EP disclosed
CN-118317963-A TRPML modulators, compositions thereof, and methods of use 卡拉韦治疗公司 2024-07-09 — — CN disclosed
WO-2011113798-A2 NEW ENZYME INHIBITOR COMPOUNDS PROXIMAGEN LIMITED (GB) 2011-09-22 — — WO disclosed
EP-2247592-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2011-08-31 — — EP disclosed
EP-2344503-A2 5-AZAINDOLE BISPHOSPHONATES Isis Innovation Ltd (GB) 2011-07-20 — — EP disclosed
WO-2011056635-A1 BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 — — WO disclosed
US-7939531-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-05-10 — — US disclosed
CN-101939324-A Pyrrolopyrazine kinase inhibitors HOFFMANN LA ROCHE 2011-01-05 — — CN disclosed
EP-2247592-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-11-10 — — EP disclosed
WO-2010033981-A2 5-AZAINDOLE BISPHOSPHONATES ISIS INNOVATION LTD. (GB) 2010-03-25 — — WO disclosed
WO-2009106442-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 — — WO disclosed
US-20090215750-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398812-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE MCOLN1, PKD2, MCOLN3 PIM1 4693/4885HASPIN 1587/4885CCNT1 4343/4885
US-20090215750-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, JAK2 PIM1 168/4885HASPIN 1103/4885CCNT1 3167/4885
US-20250136606-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE MCOLN1, TRPM2, PKD2 PIM1 4683/4885HASPIN 1525/4885CCNT1 4399/4885
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof LDHB, LDHA, PDHA1 PIM1 1672/4885HASPIN 1927/4885CCNT1 236/4885
US-20240368087-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF LDHB, LDHA, PDHA1 PIM1 1672/4885HASPIN 1927/4885CCNT1 236/4885
US-12404275-B2 Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof JAK2, TYK2, JAK1 PIM1 179/4885HASPIN 1386/4885CCNT1 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.